In recent trading session, Channel Therapeutics Corporation (AMEX:CHRO) saw 1.41 million shares changing hands at last check today with its beta currently measuring 3.51. Company’s recent per share price level of $1.35 trading at $0.18 or 15.38% at last check today assigns it a market valuation of $8.91M. That most recent trading price of CHRO’s stock is at a discount of -181.48% from its 52-week high price of $3.80 and is indicating a premium of 66.67% from its 52-week low price of $0.45. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 26240.0 shares which gives us an average trading volume of 698.16K if we extend that period to 3-months.
For Channel Therapeutics Corporation (CHRO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Channel Therapeutics Corporation (AMEX:CHRO) trade information
Upright in the green today for gaining 15.38%, in the last five days CHRO remained trading in the green while hitting it’s week-highest on Friday, 06/27/25 when the stock touched $1.35 price level, adding 23.73% to its value on the day. Channel Therapeutics Corporation’s shares saw a change of -6.37% in year-to-date performance and have moved 17.39% in past 5-day. Channel Therapeutics Corporation (AMEX:CHRO) showed a performance of 39.90% in past 30-days. Number of shares sold short was 76911.0 shares which calculate 0.88 days to cover the short interests.
Channel Therapeutics Corporation (AMEX:CHRO)’s Major holders
Insiders are in possession of 53.87% of company’s total shares while institution are holding 13.60 percent of that, with stock having share float percentage of 29.48%. Investors also watch the number of corporate investors in a company very closely, which is 13.60% institutions for Channel Therapeutics Corporation that are currently holding shares of the company.
On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund are the top two Mutual Funds which own company’s shares. As of Apr 30, 2025 , the former fund manager was holding 8.22 shares of worth $10661.0 or 0.12% of the total outstanding shares. The later fund manager was in possession of 1.85 shares on Apr 30, 2025 , making its stake of worth around $2396.0 in the company or a holder of 0.03% of company’s stock.
